Adial Pharmaceuticals (ADIL) Competitors $0.44 -0.01 (-3.27%) As of 02:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. FNCH, SXTC, OVID, NAII, SLGL, BIVI, CGTX, CMMB, ASBP, and LGVNShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Finch Therapeutics Group (FNCH), China SXT Pharmaceuticals (SXTC), Ovid Therapeutics (OVID), Natural Alternatives International (NAII), Sol-Gel Technologies (SLGL), BioVie (BIVI), Cognition Therapeutics (CGTX), Chemomab Therapeutics (CMMB), Aspire Biopharma (ASBP), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Finch Therapeutics Group China SXT Pharmaceuticals Ovid Therapeutics Natural Alternatives International Sol-Gel Technologies BioVie Cognition Therapeutics Chemomab Therapeutics Aspire Biopharma Longeveron Adial Pharmaceuticals (NASDAQ:ADIL) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Does the media refer more to ADIL or FNCH? In the previous week, Adial Pharmaceuticals had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Adial Pharmaceuticals and 0 mentions for Finch Therapeutics Group. Adial Pharmaceuticals' average media sentiment score of 0.96 beat Finch Therapeutics Group's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Adial Pharmaceuticals Positive Finch Therapeutics Group Neutral Do analysts recommend ADIL or FNCH? Adial Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 1,726.48%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Adial Pharmaceuticals is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, ADIL or FNCH? Adial Pharmaceuticals has higher earnings, but lower revenue than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$5.12M-$1.46-0.30Finch Therapeutics Group$110K200.02-$74.75M-$8.82-1.55 Is ADIL or FNCH more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -168.25% -148.46% Finch Therapeutics Group N/A -69.14%-26.92% Which has more volatility and risk, ADIL or FNCH? Adial Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Does the MarketBeat Community prefer ADIL or FNCH? Adial Pharmaceuticals received 100 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 58.51% of users gave Adial Pharmaceuticals an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformAdial PharmaceuticalsOutperform Votes11058.51% Underperform Votes7841.49% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Do insiders and institutionals have more ownership in ADIL or FNCH? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 5.2% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAdial Pharmaceuticals beats Finch Therapeutics Group on 11 of the 17 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.46M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.308.8727.2520.01Price / SalesN/A263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book0.186.617.124.70Net Income-$5.12M$144.20M$3.24B$248.05M7 Day Performance-33.45%3.88%2.75%2.62%1 Month Performance-28.31%11.26%9.00%6.32%1 Year Performance-65.78%3.96%31.41%13.78% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.2342 of 5 stars$0.44-3.3%$8.00+1,726.5%-66.2%$3.46MN/A-0.3020News CoverageShort Interest ↓Gap DownFNCHFinch Therapeutics Group0.3556 of 5 stars$13.60+0.7%N/A+885.6%$21.84M$110K-1.54190SXTCChina SXT Pharmaceuticals0.4897 of 5 stars$1.32-5.0%N/A-77.6%$20.89M$1.82M0.0090Short Interest ↑Gap DownOVIDOvid Therapeutics4.4394 of 5 stars$0.29+6.5%$2.78+860.1%-89.7%$20.62M$548K-0.6260News CoverageNAIINatural Alternatives International0.7815 of 5 stars$3.31-0.4%N/A-48.0%$20.43M$125.48M-2.56290News CoveragePositive NewsShort Interest ↑SLGLSol-Gel Technologies2.7391 of 5 stars$7.32+1.5%$40.00+446.7%-7.7%$20.38M$12.10M-21.5250Short Interest ↓BIVIBioVie2.4738 of 5 stars$1.07+2.9%$3.00+180.4%+124.3%$19.86MN/A-0.1110Positive NewsCGTXCognition Therapeutics3.6664 of 5 stars$0.32+32.6%$5.63+1,674.4%-84.7%$19.65MN/A-0.3320Positive NewsShort Interest ↓High Trading VolumeCMMBChemomab Therapeutics3.6046 of 5 stars$1.35+2.3%$8.50+529.6%+20.3%$19.39MN/A-1.3520News CoveragePositive NewsASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageGap DownLGVNLongeveron3.5342 of 5 stars$1.25+0.8%$8.67+593.3%+65.9%$18.66M$2.23M-0.2020News CoverageGap Down Related Companies and Tools Related Companies Finch Therapeutics Group Alternatives China SXT Pharmaceuticals Alternatives Ovid Therapeutics Alternatives Natural Alternatives International Alternatives Sol-Gel Technologies Alternatives BioVie Alternatives Cognition Therapeutics Alternatives Chemomab Therapeutics Alternatives Aspire Biopharma Alternatives Longeveron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
